Abstract
Obesity with insulin-resistant diabetes and increased cancer risk is a global problem. We consider the alterations of metabolism attendant on the underlying pathogenic overnutrition and the role of the growth hormone (GH)–IGF-1 axis in this interaction. Obesity-induced insulin resistance is a determinant of diabetes. Excess glucose, and an elevated concentration of insulin acting through its own receptors along with complex interactions with the IGF-1 system, will add extra fuel and fuel signalling for malignant growth and induce anti-apoptotic activities, permitting proliferation of forbidden clones. In Ecuador there are ~100 living adults with lifelong IGF-1 deficiency caused by a GH receptor (GHR) mutation who, despite a high percentage of body fat, have markedly increased insulin sensitivity compared with age- and BMI-matched control relatives, and no instances of diabetes, which is present in 6% of unaffected relatives. Only 1 of 20 deceased individuals with GHR deficiency died of cancer vs 20% of ~1,500 relatives. Fewer DNA breaks and increased apoptosis occurred in cell cultures exposed to oxidant agents following addition of serum from GHR-deficient individuals vs serum from control relatives. These changes were reversible by adding IGF-1 to the serum from the GHR-deficient individuals. The reduction in central regulators of pro-ageing signalling thus appears to be the result of an absence of GHR function. The complex inter-relationship of obesity, diabetes and cancer risk is related to excess insulin and fuel supply, in the presence of heightened anti-apoptosis and uninhibited DNA damage when GHR function is normal.
Similar content being viewed by others
Abbreviations
- GH:
-
Growth hormone
- GHR:
-
Growth hormone receptor
- IGFBP:
-
IGF-1-binding protein
- MAPK:
-
Mitogen-activated phosphokinase
- PI3K:
-
Phosphatidylinositol 3-kinase
- PKA:
-
Protein kinase A
- TOR:
-
Target of rapamycin
References
Burke-Gaffney H (1968) The history of medicine in African countries. Med Hist 12:31–412
Gohdes D, Kaufman S, Valway S (1993) Diabetes in American Indians. An overview. Diabetes Care 6:239–243
Steyn K, Fourie J, Bradshaw D (1992) The impact of chronic diseases of lifestyle and their major risk factors on mortality in South Africa. S Afr Med J 82:227–231
Reaven G (1988) Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607
Phillips C, Keese-Guoyot E, McManus R et al (2012) High dietary saturated fat intake accentuates obesity risk associated with the fat mass and obesity-associated gene in adults. J Nutr 142:824–831
Belpomme D, Irigaray P, Hardell R et al (2007) The multitude and diversity of environmental carcinogens. Environ Res 105:414–429
Wolin KY, Carson K, Colditz GA (2010) Obesity and cancer. Oncologist 15:556–565
Knudeson A (2001) Two genetic hits to cancer. Nat Rev Cancer 2:157–162
Pollak M, Schernhammer E, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–518
Hsu I, Kim S, Kabir M, Bergman R (2007) Metabolic syndrome, hyperinsulinaemia, and cancer. Am J Clin Nutr 86:867–871
Otake S, Takeda H, Suzuki Y et al (2005) Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 11:3642–3646
Thissen J, Ketelslegers H, Underwood L (1994) Nutritional regulation of the insulin like growth factors. Endocrinol Rev 15:80–101
Dupont J, Kahan J, Bao-He Q, Metzler P, Helman L, LeRoith D (2001) Insulin and IGF-I induce different patterns of expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 142:4969–4975
Guevara-Aguirre J, Al R, Guevara-Aguirre M, Saavedra J, Procel P (2013) Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-term growth effects. J Clin Endocrinol Metab 98:839–845
Longo V, Fontana L (2010) Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 31:89–98
Milazzo G, Giorgino F, Damante G et al (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52:3924–3930
Birsoy K, Possemato R, Lorbeer FK et al (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508:108–112
Baserga R, Peruzzi F, Krystof R (2003) The IGF-I receptor in cancer biology. Int J Cancer 107:873–877
Ferguson R, Novossyadlyy R, Fierz Y et al (2012) Hyperinsulinaemia enhances c-Myc-mediated mammary tumour development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14:R8
Klement R, Kämmerer U (2011) Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond) 8:75
Drake I, Sonestedt D, Gulberg B et al (2012) Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö diet and cancer cohort. Am J Nutr 96:1409–1418
Samani A, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF-I system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47
Rosenbloom A, Goldstein S, Yip CC (1976) Insulin binding to cultured human fibroblasts increases with normal and precocious aging. Science 193:412–415
Wijsman C, Rozing M, Streefland T, Leiden Longevity Study group et al (2011) Familial longevity is marked by enhanced insulin sensitivity. Aging Cell 10:114–121
Benetou B, Trichopoulou A, Orfanos P et al (2008) Conformity to traditional Mediterranean diet and cancer incidence: the Greek EPIC cohort. Brit J Cancer 99:191–195
Colman R, Anderson R, Johnson S et al (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201–204
Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140–156
Ikeno Y, Hubbard GB, Lee S et al (2009) Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 64:522–529
Dossus L, Kaaks R (2004) Nutrition, metabolic factors and cancer risk. Nat Cancer Rev 4:579–591
Sancar A, Lindsey-Boltz L, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann Rev Biochem 73:39–85
van Heijst J, Niessen H, Hoekman K, Schalkwijk CG (2005) Advanced glycation end products in human cancer tissues: detection of Nε-(carboxymethyl)lysine and argpyrimidine. Ann NY Acad Sci 1043:725–733
Dingli D, Chalub F, Santos F, van Segbroeck S, Pacheco J (2009) Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br J Cancer 101:1130–1138
Halberg H, Henriksen M, Soderhamn N et al (2005) Effect of intermittent fasting and re-feeding on insulin action in healthy men. J Appl Physiol 99:2128–2136
Lee P, Durham S, Martínez V, Vásconez O, Powell D, Guevara-Aguirre J (1997) Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. J Clin Endocrinol Metab 82:2266–2274
Wolpin B, Michaud D, Giovannucci E et al (2007) Circulating insulin-like growth factor binding protein-I and the risk of pancreatic cancer. Cancer Res 67:7923–7928
Wu Y, Yakar S, Hennighausen L, LeRoith D (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 62:1030–1035
Kolb E, Gorlick R, Maris J et al (2012) Combination testing (Stage 2) of the anti-IGF-I receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 58:729–735
MacEwen E, Pastor J, Kutzke J et al (2004) IGF-I receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77–91
Chhabra Y, Waters J, Brokks A (2011) Role of the growth hormone/IGF-I axis in cancer. Expert Rev Endocrinol Metab 6:71–84
Belfioiri A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586–623
Rinderknecht E, Humbel R (1978) The amino acid sequence of human insulin growth factor-I and its structural homology with pro-insulin. J Biol Chem 253:2769–2776
Brzozowski A, Dodson E, Dodson G et al (2002) Structural origins of the functional divergence of human insulin growth factor-I and insulin. Biochemistry 41:9389–9397
Kim J, Accili D (2002) Signaling through IGF-I and insulin receptors: where is the specificity? Growth Horm IGF Res 12:84–90
Huo J, Xu S, Lin B, Chng WJ, Lam KP (2013) Fas apoptosis inhibitory molecule is upregulated by IGF-I signaling and modulates Akt activation and IRF4 expression in multiple myeloma. Leukemia 27:1165–1171
Hanahan D, Weinberg R (2000) The hallmarks of cancer. Cell 100:57–70
Renehan A, Zwahalen M, Minder C, O’Dwyer S, Shalet M, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF-binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353
Huang J, Morehouse C, Streicher K et al (2011) Altered expression of insulin receptor isoforms in breast cancer. PLoS ONE 6:e26177
Margel D, Urbach D, Lipscombe L et al (2013) Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 31:3069–3075
Currie C, Poole C, Jenkins-Jones S, Gale E, Johnson J, Morgan C (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin in survival. Diabetes Care 35:299–304
Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546
Yakar S, LeRoith D, Brodt P (2005) The role of growth hormone /insulin-like growth factor axis in tumour growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420
Resnicoff M, Copolla D, Sell C et al (1994) Growth inhibition of human melanoma cells in nude mice by anti-sense strategies to the type-I insulin-like growth factor receptor. Cancer Res 54:4848–4850
Suh Y, Atzmon G, Cho M et al (2008) Functionally significant insulin-like growth factor-I receptor mutations in centenarians. Proc Natl Acad Sci 105:3438–3442
Guevara-Aguirre J, Rosenbloom A, Fielder PJ, Diamond FB Jr, Rosenfeld RG (1993) Growth hormone receptor deficiency in Ecuador: clinical and biochemical phenotype in two populations. J Clin Endocrinol Metab 76:417–423
Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Fielder PJ (1990) The little women of Loja: growth hormone receptor deficiency in an inbred population of Southern Ecuador. N Engl J Med 323:1367–1374
Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M et al (2011) Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3:70ra13
Steuerman R, Shivah O, Laron Z (2011) Congenital IGF-I deficiency tends to confer protection against postnatal development of malignancies. Eur J Endocrinol 164:485–489
Gebre-Medhin M, Kindblom LG, Wennbo H, Törnell J, Meis-Kindblom JM (2001) Growth hormone receptor is expressed in human breast cancer. Am J Pathol 158:1217–1222
Zhou D, Yang J, Huang WD, Wang J, Zhang Q (2013) siRNA-targeted inhibition of growth hormone receptor in human colon cancer SW480 cells. World J Gastroenterol 19:8108–8113
Guevara Aguirre J, Rosenbloom AL, Balasubramaniam P et al (2014) Enhanced insulin sensitivity in subjects with absent growth hormone receptor signaling despite increased body fat content. The Endocrine Society, Chicago, June 21-24, latebreaking abstract LB-OR02-1 (abstract)
Laron Z (2011) Insulin secretion and carbohydrate metabolism in patients with Laron syndrome: from hypoglycaemia to diabetes mellitus. In: Laron Z, Kopchick JJ (eds) Laron syndrome from man to mouse. Springer-Verlag, Berlin/Heidelberg, pp 259–272
Vicente TAR, Rocha IES, Salvatori R et al (2013) Lifetime congenital isolated GH deficiency does not protect from the development of diabetes. Endocr Connect 2:112–117
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
Contribution statement
JG-A provided the initial draft, which was edited and finalised by both authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guevara-Aguirre, J., Rosenbloom, A.L. Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency. Diabetologia 58, 37–42 (2015). https://doi.org/10.1007/s00125-014-3397-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-014-3397-3